European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC

Affiliations

• ¹ Division of Evidence-Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
• ² Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands.
• ³ Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
• ⁴ Department of Dermatology, Paul Sabatier University, Toulouse, France.
• ⁵ Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen, UK.
• ⁶ Service de Dermatologie, Hôpital Ambroise Paré Université Paris V, Boulogne, France.
• ⁷ St Johns Institute of Dermatology, Guys and St Thomas' Hospital Foundation Trust, London, UK.
• ⁸ Hospital Universitario de la Princesa, Madrid, Spain.
• ⁹ Radboud University medical center and Radboud University, Nijmegen, The Netherlands.
• ¹⁰ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
• ¹¹ Cambridge, UK.
• ¹² Roma, Italy.
• ¹³ Department of Dermatology, Psoriasis-Center University Medical Center Schleswig Holstein, Kiel, Germany.
• ¹⁴ Waterloo, Canada.
• ¹⁵ Dermatologikum Hamburg, Hamburg, Germany.
• ¹⁶ Section of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden.